DNA-PKcs promotes therapy resistance and metastatic recurrence in neuroblastoma
Our findings correlate elevated DNA-PKcs levels with poor patient prognosis and show that low-dose radiotherapy combined with peposertib effectively abrogates neuroblastoma self-renewal compared to chemotherapy-based regimens, thereby implicating DNA-PKcs as a key mediator of metastatic relapse and supporting radiotherapy plus DNA-PKcs inhibition as a compelling therapeutic strategy for relapsed or refractory high-risk neuroblastoma.
Authors
- Katherine Somers (ORCID: https://orcid.org/0000-0001-8683-9488)
- S H Kim (ORCID: https://orcid.org/0000-0002-1224-1536)
- Eddy Shih-Hsin Yang (ORCID: https://orcid.org/0000-0002-6450-2638)
- Piotr Rychahou (ORCID: https://orcid.org/0000-0001-7352-9122)
- Natalie Wu
- Mahnaz Norouzi
- Beibei Zhu
- Eric J. Rellinger
- Chi Wang
- B. Mark Evers
Institutions
- Cincinnati Children's Hospital Medical Center (US)
- University of Kentucky (US)
- Markey Cancer Center (US)
Publication Details
- Journal
- Cancer Letters
- Published
- 2026-02-27
- DOI
- https://doi.org/10.1016/j.canlet.2026.218383
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00